Advertisement
Collaboration › Details
AstraZeneca–Proteros: small-molecule cancer drugs, 202106– collab RnD + license agreem with research funding + $62m milestones + royalties
Period | 2021-06-02 | |
Partner, 1st | AstraZeneca plc (LSE: AZN) | |
Group | AstraZeneca (Group) | |
Partner, 2nd | Proteros Biostructures GmbH | |
Group | Proteros (Group) | |
Product | small-molecule cancer drug | |
Product 2 | drug discovery | |
Person | Galbraith, Susan (AstraZeneca 201212 VP + Head Oncology Innovative Medicines Unit) | |
Proteros Biostructures GmbH. (6/2/21). "Press Release: Proteros Enters into Oncology Collaboration and License Agreement with AstraZeneca". Martinsried.
Proteros to receive research funding and milestone payments plus royalties
Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.
The collaboration brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with AstraZeneca’s expertise in target biology and medicinal chemistry to jointly discover novel lead compounds which will be further developed, manufactured, and commercialized by AstraZeneca.
Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.
“We believe that advances in epigenomic capabilities will bring forward the next wave of innovation in cancer development through the discovery and development of novel small molecules,” said Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, AstraZeneca. “Proteros’ proprietary discovery platform enables us to screen epigenetic targets in a physiologically relevant setting, supporting accelerated discovery and development of the next wave of anti-cancer medicines.”
“We are delighted AstraZeneca has selected Proteros to act as their discovery engine for a number of novel and very relevant oncology targets,” said Dr Torsten Neuefeind, Proteros’ CEO. “These types of targets pose a number of challenges that Proteros’ discovery platform is uniquely positioned to overcome.”
About Proteros biostructures GmbH
Proteros is a privately held early-stage services provider in structure-based drug discovery with a cutting-edge discovery engine tailored to unlock even the most technically challenging targets. Proteros’ work is built on scientific excellence and supports its clients to reach the right results and accelerate their overall research timelines. Proteros supports most of the world’s 20 largest pharma companies and more than 250 pharmaceutical and biotech partners in the US, Europe and Japan.
For more information please visit www.proteros.com.
Proteros contact information
Dr. Torsten Neuefeind
Chief Executive Officer
Phone: +49 89 700761-0
Email: info@proteros.com
Record changed: 2022-11-19 |
Advertisement
More documents for AstraZeneca (Group)
- [1] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
- [2] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
- [3] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
- [4] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....
- [5] Icosavax, Inc.. (12/12/23). "Press Release: Icosavax, Inc. Announces Agreement to Be Acquired by AstraZeneca". Seattle, WA....
- [6] AstraZeneca plc. (12/12/23). "Press Release: AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data"....
- [7] AstraZeneca plc. (11/20/23). "Press Release: AstraZeneca Launches Evinova, a Health-tech Business to Accelerate Innovation across the Life Sciences Sector, the Delivery of Clinical Trials and Better Health Outcomes"....
- [8] AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]"....
- [9] Nanoform Finland Oyj. (10/23/23). "Press Release: Nanoform Grant Global Starmap AI License to AstraZeneca". Helsinki....
- [10] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top